Novel N-1 substituted fluoroquinolones inhibit human topoisomerase I activity and exhibit anti-proliferative activity.
Oppegard LM, Delgado JL, Kulkarni CA, Towle TR, Hart DE, Williams BP, Lentz SRC, Norris BJ, Flory CM, Schumacher RJ, Murry DJ, Kerns RJ, Hiasa H.
Oppegard LM, et al. Among authors: kerns rj.
Invest New Drugs. 2019 Apr;37(2):378-383. doi: 10.1007/s10637-018-0666-x. Epub 2018 Sep 10.
Invest New Drugs. 2019.
PMID: 30198058
Free PMC article.